Shattuck Labs Q3 net loss $10.1M; SL-325 Phase 1 dosing underway; $103M private placement

Shattuck Labs, Inc.

2025-Q3 EPS reported -$0.62 revenue$1,000,000

First participants dosed in Phase 1 trial of SL-325 (DR3 antagonist) in healthy volunteers; SAD/MAD enrollment expected Q2 2026.
Closed $103M private placement in August 2025; cash runway extended into 2029 assuming full warrant exercise.
Net loss $10.1M ($0.14/sh) vs $16.6M ($0.33/sh) in Q3 2024; R&D expenses down to $7.6M from $16.3M.
Appointed Dan Baker, M.D. and Mona Ashiya, Ph.D. to Board of Directors in August 2025.
Cash and equivalents $86.1M as of Sept 30, 2025; funding to support SL-325 through Phase 2 and other milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.